Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ABREVA vs ANEXSIA 7.5/650
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Inhibits viral DNA polymerase and DNA synthesis of herpes simplex virus (HSV-1 and HSV-2).
Hydrocodone is a mu-opioid receptor agonist that inhibits ascending pain pathways and alters pain perception; acetaminophen inhibits cyclooxygenase (COX) enzymes, primarily in the CNS, reducing prostaglandin synthesis and fever.
Herpes labialis (cold sores) in immunocompetent adults and adolescents ≥12 years
Management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate
Apply a thin layer to the affected area 5 times daily for 4 days.
1 tablet orally every 4 to 6 hours as needed; maximum 6 tablets per day.
Due to minimal systemic absorption, an elimination half-life cannot be accurately determined in humans. Following intravenous administration in animals, the terminal half-life is approximately 10 hours, but this is not clinically relevant for topical use.
Hydrocodone: Terminal half-life 3.8-7.2 hours (mean 5.6 h). Acetaminophen: 1.5-2.5 hours (therapeutic) but prolonged to >4 hours in overdose with hepatotoxicity risk.
Docosanol is applied topically with minimal systemic absorption. No significant metabolism occurs. No active metabolites.
Hydrocodone: CYP3A4 and CYP2D6; acetaminophen: primarily liver glucuronidation (UGT1A1, UGT1A6, UGT1A9) and sulfation (SULT1A1, SULT1A3), with minor CYP2E1 oxidation.
Docosanol is minimally absorbed after topical application; systemic absorption is negligible. Any absorbed drug is primarily metabolized and excreted via bile and feces. Renal excretion is insignificant. Less than 1% of the applied dose enters systemic circulation, and nearly all elimination occurs via biliary/fecal routes.
Hydrocodone: Renal elimination of metabolites (hydromorphone, norhydrocodone) and unchanged drug accounts for ~60-90% of clearance. Acetaminophen: ~85% of dose is excreted in urine as glucuronide and sulfate conjugates; 5-10% unchanged; 2-5% as mercapturate.
Renally negligible; not extensively studied. For the absorbed fraction, protein binding is presumed to be high (>99%) due to the lipophilic nature of docosanol, binding primarily to albumin and lipoproteins.
Hydrocodone: ~36% bound to serum proteins. Acetaminophen: 10-25% bound (minimal binding).
Systemic absorption is minimal; thus Vd is not clinically relevant. Based on animal studies, Vd is estimated to be approximately 1.5 L/kg, reflecting distribution into total body water and lipid compartments.
Hydrocodone: Vd ~3-5 L/kg (wide distribution). Acetaminophen: Vd ~0.9-1.0 L/kg (primarily body water).
Topical administration: bioavailability is less than 1% due to minimal percutaneous absorption; systemic exposure is negligible. Not administered via other routes.
Oral: Hydrocodone ~70-80% (variable first-pass). Acetaminophen ~63-89% (mean 75-80%).
No dosage adjustment required.
Cr Cl <30 m L/min: contraindicated; Cr Cl 30-60 m L/min: maximum 3 tablets per day; given the hydrocodone component, avoid in severe renal impairment.
No dosage adjustment required.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose by 50% and monitor; Child-Pugh Class C: contraindicated due to hydrocodone.
Approved for use in patients aged 12 years and older: apply a thin layer 5 times daily for 4 days.
Not recommended in pediatric patients due to risk of respiratory depression; for ages <18, contraindicated.
No specific dosage adjustment required; use same as adult dosing.
Initiate with lowest effective dose, monitor for respiratory depression and constipation; maximum 4 tablets per day in patients >65 years.
None.
Risk of addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion (especially in children) can be fatal; neonatal opioid withdrawal syndrome; cytochrome P450 3A4 interaction (concomitant use with CYP3A4 inhibitors may increase hydrocodone levels); risk of medication errors (confusion between different strengths).
Not for ophthalmic, intranasal, intravaginal, or intraoral use.,Avoid application to mucous membranes.,Immunocompromised patients: consider alternative therapy for severe infections.,Local irritation or allergic contact dermatitis may occur.
Addiction, abuse, and misuse; respiratory depression; neonatal opioid withdrawal syndrome; interactions with CNS depressants; risk of serotonin syndrome with serotonergic drugs; adrenal insufficiency; hypotension; seizures; gastrointestinal obstruction; severe cutaneous reactions (acetaminophen); hepatotoxicity (acetaminophen overdose); acute abdominal conditions; impaired mental/physical abilities; elderly/debilitated patients; renal/hepatic impairment.
Hypersensitivity to docosanol or any component of the formulation.
Significant respiratory depression; acute or severe bronchial asthma (without monitoring or resuscitative equipment); known or suspected gastrointestinal obstruction (including paralytic ileus); hypersensitivity to hydrocodone or acetaminophen; use with MAOIs or within 14 days of such therapy.
No known food interactions. Avoid acidic or spicy foods if they irritate the lesion. Maintain good hydration and nutrition to support immune function.
Avoid alcohol due to increased risk of acetaminophen hepatotoxicity and additive CNS depression. Grapefruit juice may increase hydrocodone absorption; consider avoiding. No other significant food interactions.
FDA Pregnancy Category B. Animal studies have not demonstrated fetal risk. No adequate human studies in pregnant women. Risk to fetus cannot be ruled out, but potential benefits may warrant use. No first trimester-specific risks identified.
FDA Category C. First trimester: Possible increased risk of cardiac defects with oxycodone. Second/third trimester: Chronic use may lead to neonatal opioid withdrawal syndrome; no clear teratogenicity. Acetaminophen is generally safe, but high doses may be hepatotoxic.
Excretion in human milk unknown. Caution advised. M/P ratio not established.
Oxycodone: M/P ratio ~0.8-3; present in milk; risk of neonatal sedation. Acetaminophen: M/P ~0.8-1, low risk. Avoid due to oxycodone; consider alternative analgesic.
No dose adjustment required. Pharmacokinetics not significantly altered in pregnancy.
Increased clearance of oxycodone in pregnancy may require increased dose; acetaminophen pharmacokinetics unchanged. Adjust based on pain control and withdrawal risk.
Apply at first prodromal symptoms (tingling, burning) for maximal efficacy. Avoid application to mucous membranes or inside the nose/mouth. Use a fingertip to apply a thin layer to the lesion; do not share the tube. Lesions should be kept clean and dry; avoid coverings unless instructed. Consider combination therapy with oral antivirals for frequent or severe outbreaks.
Fixed-dose combination of hydrocodone bitartrate (7.5 mg) and acetaminophen (650 mg). Hydrocodone is a schedule II controlled substance with high abuse potential. Acetaminophen hepatotoxicity risk increases above 3 g/day; prescribe no more than 4 doses per day. Monitor for respiratory depression, especially in opioid-naïve patients. Avoid in severe hepatic impairment. Use with caution in patients with COPD, sleep apnea, or concurrent CNS depressants. Consider naloxone co-prescription if high opioid dose or concurrent benzodiazepine use.
Start applying at the first sign of a cold sore (tingling, itching, or redness).,Wash hands before and after application to prevent spreading the virus.,Apply a small amount (pea-sized) to the affected area, typically 5 times a day until healed.,Do not use on broken skin or mucous membranes (inside mouth, eyes, or genital area).,Avoid kissing or sharing utensils, towels, or lip products while the sore is present.,The tube is for single-patient use only; do not share with others.,May cause mild stinging or redness; if severe irritation occurs, discontinue use.,See a doctor if the sore is severe, lasts longer than 10 days, or you have frequent outbreaks.
Take exactly as prescribed; do not increase dose or frequency.,Do not take with alcohol or other medications containing acetaminophen.,May cause drowsiness or dizziness; avoid driving or operating machinery until effects are known.,Store securely out of reach of children and others; dispose of unused tablets properly.,Seek emergency care for difficulty breathing, severe sedation, or signs of allergic reaction.,Do not abruptly stop after prolonged use; withdrawal symptoms may occur.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ABREVA vs ANEXSIA 7.5/650, answered by our medical review team.
ABREVA is a Antiviral that works by Inhibits viral DNA polymerase and DNA synthesis of herpes simplex virus (HSV-1 and HSV-2).. ANEXSIA 7.5/650 is a Opioid Analgesic Combination that works by Hydrocodone is a mu-opioid receptor agonist that inhibits ascending pain pathways and alters pain perception; acetaminophen inhibits cyclooxygenase (COX) enzymes, primarily in the CNS, reducing prostaglandin synthesis and fever.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ABREVA and ANEXSIA 7.5/650 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ABREVA is: Apply a thin layer to the affected area 5 times daily for 4 days.. The standard adult dose of ANEXSIA 7.5/650 is: 1 tablet orally every 4 to 6 hours as needed; maximum 6 tablets per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ABREVA and ANEXSIA 7.5/650 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ABREVA is classified as Category C. FDA Pregnancy Category B. Animal studies have not demonstrated fetal risk. No adequate human studies in pregnant women. Risk to fetus cannot be ruled out, but potential benefits ma. ANEXSIA 7.5/650 is classified as Category C. FDA Category C. First trimester: Possible increased risk of cardiac defects with oxycodone. Second/third trimester: Chronic use may lead to neonatal opioid withdrawal syndrome; no . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.